| Dr Jennifer Dennis, PHARM D | |
|
225 Shelly Ln, Poplar Bluff, MO 63901-7734 | |
| (573) 785-8218 | |
| (573) 785-8125 |
| Full Name | Dr Jennifer Dennis |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 225 Shelly Ln, Poplar Bluff, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215014865 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 2006021569 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Dennis, PHARM D 225 Shelly Ln, Poplar Bluff, MO 63901-7734 Ph: (573) 718-2840 | Dr Jennifer Dennis, PHARM D 225 Shelly Ln, Poplar Bluff, MO 63901-7734 Ph: (573) 785-8218 |
News Archive
On the sidelines of the U.N. High-level Meeting on Non-Communicable Diseases (NCDs) on Tuesday, "representatives of governments, civil society and the private sector joined United Nations agencies ... to emphasize the importance of good nutrition, which is vital not only for human health but also for national economic and social development," the U.N. News Centre reports.
A team of scientists from the USA and Germany has recently studied the evolution of SARS-CoV-2 in a representative set of sequences from the USA collected between 2020 and 2021. The findings reveal that the viral genome has accumulated multiple mutations over time with only occasional loss of mutation. The main driving forces behind such genetic variations include widespread infection and superspreader events.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
› Verified 3 days ago
Janet Lee Turner, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1500 N Westwood Blvd, Poplar Bluff, MO 63901 Phone: 573-778-4240 | |
Ashley Malkowski, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1301 Shelby Rd, Poplar Bluff, MO 63901 Phone: 573-778-9156 | |
Dr. Kelly Maxwell, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1500 N Westwood Blvd, Poplar Bluff, MO 63901 Phone: 573-686-4151 | |
Mr. John Judson Kersbergen, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2233 N Westwood Blvd, Poplar Bluff, MO 63901 Phone: 573-785-4557 Fax: 573-686-0970 | |
Mr. Gary Michael Simmons, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 909 W Pine St, Suite 1, Poplar Bluff, MO 63901 Phone: 573-785-0984 Fax: 573-785-2257 | |
Mary Farris, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1875 N Westwood Blvd, Poplar Bluff, MO 63901 Phone: 573-785-1461 Fax: 573-785-0831 | |
Patrick Hyatt, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2233 N Westwood Blvd, Poplar Bluff, MO 63901 Phone: 573-785-4557 |